Tempus AI Diagnostics Growth Highlighted Amid Persistent Profitability and Acquisition Risks

What happened

A Zacks article reports Tempus AI's diagnostics arm is surging in 2025, driven by precision oncology testing, MRD adoption, AI tools, and the Ambry Genetics acquisition. The DeepValue master report confirms this growth, with FY2025 diagnostics revenue up 111.5% YoY and Q4 2025 adjusted EBITDA turning positive at $12.9M. However, the report critically notes persistent cash burn, as operating cash flow worsened to -$181.3M for nine months ended September 2025 and accounts receivable rose to $311.2M, indicating poor cash conversion. The Ambry acquisition adds growth potential but introduces high risks, with goodwill at $470.2M and intangibles at $355.3M, and the auditor flagging customer relationship valuation as a critical audit matter. Investors are now focused on whether Tempus can sustain volume growth and achieve the FY2026 adjusted EBITDA guide of ~$65M without further dilution, as the stock embeds growth but incomplete confidence in profitability.

Implication

The positive diagnostics growth story must be balanced against the need for consistent adjusted EBITDA improvements to validate the FY2026 guide. High accounts receivable and negative operating cash flow suggest revenue growth isn't translating to cash, which could pressure liquidity if not addressed. The Ambry acquisition's success is crucial, as any underperformance could lead to impairment charges and hurt the balance sheet. With a full valuation allowance on DTAs and prior reliance on equity financing, investors must watch for signs of self-sufficiency in cash generation. Key checkpoints include quarterly diagnostics volumes, MRD adoption rates, and disclosures on Ambry performance to assess the investment thesis.

Thesis delta

The new article corroborates the growth drivers cited in the DeepValue report, such as MRD adoption and Ambry integration, reinforcing the diagnostics expansion narrative. However, it does not alter the critical investment thesis, which hinges on Tempus delivering sustained adjusted EBITDA and managing acquisition risks over the next 6-12 months. Investors should remain cautious and await concrete evidence from upcoming financial reports to validate the growth narrative beyond the highlighted drivers.